Back to Journals » Cancer Management and Research » Volume 12

SOX10 – A Novel Marker for the Differential Diagnosis of Breast Metaplastic Squamous Cell Carcinoma

Authors Qi J, Hu Z, Xiao H, Liu R, Guo W, Yang Z, Ma K, Su S, Tang P, Zhou X, Zhou J, Wang K

Received 22 February 2020

Accepted for publication 23 April 2020

Published 28 May 2020 Volume 2020:12 Pages 4039—4044


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Eileen O'Reilly

Jialin Qi,1,2,* Zhenmin Hu,1,2,* Heng Xiao,3 Ruijie Liu,2 Wei Guo,4 Zhichun Yang,5 Kewen Ma,2 Shitong Su,2 Ping Tang,1 Xunjian Zhou,2 Jianhua Zhou,1,2 Kuansong Wang1,2

1Department of Pathology, School of Basic Medical Science, Central South University, Changsha 410013, People’s Republic of China; 2Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, People’s Republic of China; 3Department of Pathology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, People’s Republic of China; 4Department of Pathology, Hunan Provincial People’s Hospital, Changsha, Hunan 410005, People’s Republic of China; 5Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Kuansong Wang; Jianhua Zhou Email;

Introduction: Differential diagnosis of metaplastic squamous cell carcinoma of breast (MSCCB) is difficult. In particular, in terms of metastatic MSCCB, because of the low speciality of traditional markers such as mammaglobin, gross cystic disease fluid protein-15 (GCDFP-15) and GATA binding protein 3 (GATA3), the most common problem is differentiating the spread of MSCCB to the lung from a primary lung squamous cell carcinoma. It is urgently required to explore a novel marker to aid in differential diagnosis.
Aim: The aim of this study is to explore a novel marker to aid in the differential diagnosis of MSCCB from other squamous cell carcinomas (SCC) in other organs.
Methods: We tested the expression of SOX10 in 375 human SCC specimens with immunohistochemistry (IHC).
Results: In a series of 20 MSCCB, 9 (45%) were positive for SOX10. All of them were triple-negative MSCCB. Conversely, SOX10 was totally negative in another 205 SCC originating from lung, skin, cervix, oral mucosa, and esophagus. In a series of 150 triple-negative breast cancer and their metastatic foci, SOX10 labeling in the primary tumor and metastasis was 78% and 79.3%, respectively, and the agreement rate was 97.3% (P> 0.05).
Conclusion: Our findings demonstrate that SOX10 was recommended for differentiating MSCCB from non-mammary metastasis to the breast, as well as for distinguishing primary SCC from metastatic MSCCB, and SOX10 may be valuable in the pathological diagnosis of breast-derived metaplastic squamous cell carcinoma.

Keywords: SOX10, squamous cell carcinoma, breast, lung, differential diagnosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]